## **Nuclear Medicine Technology Certification Board**

**CNMT Certification Examination Content Outline** 



## **Components of Preparedness**

**Domain I:** Radiation Physics & Detection – 7% **Domain II:** Radiation Safety & Regulations – 13%

**Domain III:** Pharmaceutical & Radiopharmaceutical Agents – 25% **Domain IV:** Instrument Operations & Quality Control – 15%

Domain V: Clinical Procedures - 40%

#### I. Radiation Physics and Detection

**7**%

#### A. Understand the fundamentals of radiation physics and detection

- 1. Physical properties
  - a. Radioactive materials
    - i. Isotopes and their properties (e.g., half-life, energy)
    - ii. Modes of decay (e.g., gamma emitters, beta emitters, alpha emitters, positron emitters)
  - b. X-ray production
    - i. Bremsstrahlung
    - ii. Characteristic x-ray
- 2. Decay calculations and Counting statistics
- 3. Interactions of radiation with matter
  - a. Compton scatter
  - b. Photoelectric effect
- 4. Radiation detector types and basic principles
  - a. Nal well
  - b. Ion chamber
  - c. Solid state detector
  - d. GM meter

## 13%

#### II. Radiation Safety and Regulations

## A. Identify biological effects of radiation exposure

- 1. Deterministic (e.g., due to amount, radiation burns)
- 2. Stochastic (e.g., cancer)
- 3. Exposure
  - a. Patient (e.g., imaging, treatment, diagnostic)
  - b. Technologist (e.g., imaging, treatment, diagnostic)
- 4. Short-term vs Long-term effects of radiation
- 5. Radiosensitivity (e.g., effects on the cell)

#### B. Recognize protection techniques and calculations

- 1. ALARA
  - a. Time
  - b. Distance (inverse square law)
  - c. Shielding (shielding equations)

#### C. Perform survey protocols and requirements (e.g., timing and frequency)

- 1. Radiation surveys (area monitoring) including:
  - a. Survey meters and well counters
  - b. Choice of radiation detection devices (e.g., Geiger Counters, sodium iodide detectors)
  - c. Frequency of surveys
  - d. Trigger limits of surveys
- 2. Personal monitoring devices
  - a. Types (e.g., ring badge vs collar badge)
  - b. Dosimeter report
  - c. Declaration of pregnancy
- 3. Personal protective equipment (e.g., lab coat, gloves, syringe shields)
- 4. Effective dose equivalent limits for:
  - a. Radiation workers
  - b. Declared pregnant radiation workers
  - c. General public

## D. Comply with Nuclear Regulatory Commission (NRC) Regulations

- Posted warnings and informational signs delineating restricted and unrestricted areas
- 2. Surveying and inventorying radioactive materials
- 3. Adverse event response
  - a. Trigger levels and monitoring methods
  - b. Radiation exposure
  - c. Radiation spills (e.g., major vs minor)
  - d. Protection during adverse events
  - e. Personnel, patient and/or public decontamination
  - f. Area/equipment decontamination
  - g. Recordable and reportable events
- 4. Adherence to radioactive waste storage requirements
- 5. Radioactive material disposal (e.g., liquids, solids, gasses, contaminated materials)
- 6. Record maintenance
  - a. Receipt, storage, and disposal of radioactive materials
  - b. Radiation monitoring and reporting
  - c. Equipment calibration and maintenance
  - d. Staff, patient, occupational and public exposure
  - e. Nuclear medicine diagnostic and therapeutic procedures
  - f. Leak test
- 7. Written directives
- 8. Shipping and Packaging Regulations
  - a. Department of Transportation (DOT)
  - b. Types of shielding containers

- c. Label requirements (e.g., transportation index, name, concentration, expiration date/time, total activity, assay date/time, limits)
- d. Types of packages (e.g., exempt, non-exempt)
- e. Package monitoring/receiving/returning

## E. Comply with Other Regulations and Guidelines

- 1. Environmental Protection Agency (EPA)
- 2. Occupational Safety and Health Administration (OSHA)
- 3. Health and Human Services (HHS)/Health Insurance Portability and Accountability Act (HIPAA)
  - a. Protecting patient rights and privacy
  - b. Maintaining patient records
  - c. Releasing information to authorized parties
- 4. Food and Drug Administration (FDA)
- 5. United States Pharmacopeia (USP)
  - a. USP<797>
  - b. USP<825>
- 6. Institutional and Departmental Accreditation Organizations (e.g., SOP documents)

#### III. Pharmaceutical and Radiopharmaceutical Agents

#### 25%

## A. Elute radionuclide generator, perform, and evaluate quality control tests

- 1. Types of generators (e.g., 99Mo/99mTc, 82Sr/82Rb)
  - a. Transient and secular
  - b. Eluate
  - c. Generator yield volume and activity
  - d. Quality control procedures
    - i. Radionuclidic breakthrough (e.g., 99Mo breakthrough)
    - ii. Chemical (e.g., Al+3 breakthrough)
- 2. Dose calibrator operation /units of radioactivity

## B. Prepare radiopharmaceutical kits, perform quality control, and evaluate results

- 1. Radiopharmaceutical kits
  - a. Preparation techniques
  - b. Activity and volume limitations
  - c. Activity calculations
  - d. Particle size and number (e.g., MAA kit)
- 2. Radiopharmaceutical quality control
  - a. Visual inspection color and clarity
  - b. Radiochemical purity (e.g., ITLC)
- 3. Labeling kits
- 4. Storage of kits before and after reconstitution
  - a. Expiration
  - b. Temperature requirements

## C. Understand the characteristics (i.e., mechanism of localization), indications, contraindications, and administration of diagnostic radiopharmaceuticals

- 1. Tc-99m labeled radiopharmaceuticals
  - a. Tc-99m sodium pertechnetate

- b. Tc-99m oxidronate/HDP
- c. Tc-99m medronate/MDP
- d. Tc-99m pentetate/DTPA
- e. Tc-99m macroaggregated albumin/MAA
- f. Tc-99m sulfur colloid (e.g., filtered, unfiltered)
- g. Tc-99m mebrofenin (Choletec®)
- h. Tc-99m mertiatide/MAG3®
- i. Tc-99m pyrophosphate/PYP
- j. Tc-99m sestamibi/MIBI (Cardiolite®)
- k. Tc-99m tetrofosmin (Myoview®)
- l. Tc-99m succimer/DMSA (Nephroscan®)
- m. Tc-99m exametazime/HMPAO (Ceretec®)
- n. Tc-99m bicisate/ECD (Neurolite®)
- o. Tc-99m labeled RBCs (UltraTag®/PYP)
- p. Tc-99m HMPAO tagged WBCs
- q. Tc-99m tilmanocept (Lymphoseek®)
- 2. Iodine labeled radiopharmaceuticals
  - a. I-123 sodium iodide
  - b. I-131 sodium iodide
  - c. I-123 lobenguane (MIBG) (AdreView®)
  - d. I-123 Ioflupane (DaTscan®)
- 3. Indium labeled radiopharmaceuticals
  - a. In-111 chloride
  - b. In-111 oxine labeled WBCs
  - c. In-111 pentetate (DTPA)
  - d. In-111 pentetreotide (Octreoscan®)
- 4. Miscellaneous diagnostic radiopharmaceuticals
  - a. Ga-67 gallium citrate
  - b. Tl-201 thallous chloride
  - c. Xe-133 gas
- 5. Positron Emission Tomography
  - a. Cu-64 Dotatate (Detectnet®)
  - b. F-18 FDG
  - c. F-18 Florbetaben (Neuraceg®)
  - d. F-18 Florbetapir (Amyvid®)
  - e. F-18 Flutemetamol (Vizamyl®)
  - f. F-18 Sodium Fluoride (NaF)
  - g. F-18 Fluciclovine (Axumin®)
  - h. F-18 Flortaucipir (Tauvid®)
  - i. F-18 Piflufolastat (Pylarify®)
  - j. F-18 Fluorodopa
  - k. F-18 Fluoroestradiol (Cerianna®)
  - l. Ga-68 Dotatate (Netspot®)
  - m. Ga-68 Dotatoc
  - n. Ga-68 Gozetotide (Illuccix®, Locametz®)

- o. N-13 ammonia
- p. Rb-82 chloride (Rubyfill®, Cardiogen®)

# D. Understand the characteristics (i.e., mechanism of localization), indications, contraindications, and administration of therapeutic radiopharmaceuticals

- 1. I-131 sodium iodide
- 2. Lu-177 dotatate (Lutathera®)
- 3. Lu-177 Vipivotide tetraxetan (Pluvicto®)
- 4. Ra-223 Radium dichloride (Xofigo®)
- 5. Sr-89 chloride (Metastron®)
- 6. Y-90 microspheres (SIR-Spheres®, TheraSphere®)

# E. Understand the indications, contraindications, and administration of interventional and adjunct pharmaceutical agents used in conjunction with nuclear medicine procedures

- 1. Dipyridamole (Persantine®)
- 2. Adenosine
- 3. Dobutamine
- 4. Aminophylline
- 5. Regadenoson (Lexiscan®)
- 6. Captopril
- 7. Enalaprilat
- 8. Furosemide (Lasix®)
- 9. Insulin
- 10. Acetazolamide (Diamox®)
- 11. Cholecystokinin/ sincalide/CCK
- 12. Morphine
- 13. Cimetidine/famotidine
- 14. ACD solution
- 15. Heparin
- 16. Contrast media (oral and IV)
- 17. Lugol's solution/SSKI
- 18. Thyroid Stimulating Hormone (TSH)
- 19. Lidocaine
- 20. Lidocaine (EMLA®) cream
- 21. Atropine
- 22. Recombinant human TSH (Thyrogen®)
- 23. Amino acids (e.g., lys-arg)
- 24. Zofran/Emend
- 25. Beta blockers (e.g., Metoprolol)
- 26. Boost®/Ensure®

## F. Radiolabel blood components with radiopharmaceutical according to protocol

- 1. Labeling procedures
  - a. Required lab equipment and supplies
  - b. Anticoagulants and other additives
  - c. Chemical reactions
  - d. Cell washing
  - e. Required radiopharmaceuticals

- f. Method (e.g., in vivo, in vitro)
- 2. Calculation of labeling efficiency and administered dosage
- 3. Reinjection patient and sample verification

## G. Administer radiopharmaceuticals and non-radioactive agents

- 1. Administration routes (e.g., IV, oral, intrathecal)
- 2. Administration techniques (e.g., bolus, infusion, aseptic)

#### IV. Instrument Operations and Quality Control

#### 15%

## A. Operate Non-imaging equipment and components

- 1. Quality control and calibration for well counters and probes
  - a. Quality control and calibration for the sodium iodide scintillation detector
  - b. Gamma ray spectra and pulse height analysis
  - c. Formulas (e.g., energy resolution, sensitivity, Chi-square statistics)
- 2. Operational status of survey meter
  - a. Survey meter operations and components
  - b. Survey meter quality control and calibration
- 3. Dose calibrator constancy, accuracy, linearity, and geometry tests

## B. Operate Imaging equipment and components

- 1. Gamma Camera quality control
  - a. Uniformity
  - b. Spatial resolution and linearity
  - c. Visual image quality
  - d. Phantoms
  - e. Artifacts
  - f. System sensitivity
  - g. Pulse height analysis
- 2. SPECT and SPECT/CT imaging system
  - a. Attenuation correction
  - b. SPECT camera quality control
    - i. Center of rotation
    - ii. Field uniformity requirements
    - iii. Pixel calibration
    - iv. 3-D uniformity and resolution (e.g., Jaszczak phantom)
    - v. Artifacts
- 3. PET and PET/CT imaging systems
  - a. Application of attenuation corrections
  - b. PET quality control (e.g., daily blank scan, normalization scan, 2-D/3- D well counter, artifacts)
- 4. CT imaging systems
  - a. Co-registration of images
  - b. CT quality control (e.g., contrast and spatial resolution, noise, uniformity, artifacts)
  - c. Safety alerts (e.g., pre-scan notification)
- 5. Computer equipment (e.g., monitors, matrix sizes, printers)
- 6. Networking and information systems (e.g., PACS and RIS)

## C. Operate Auxiliary equipment

- 1. Laboratory equipment (e.g., pipette, fume hoods)
- 2. Patient care equipment
  - a. Intravenous infusion pump
  - b. ECG monitor
  - c. Pulse oximeter
  - d. Defibrillator
  - e. Glucose meter
  - f. Blood pressure equipment
  - g. Oxygen delivery equipment
  - h. Patient lifts
  - i. Lateral transfer equipment
- 3. Non-imaging equipment
  - a. Xenon delivery system and trap
  - b. Aerosol delivery system
  - c. Treadmill
  - d. Liquid scintillation counter
  - e. Rb delivery system (e.g. Rubyfill®, Cardiogen®)

## V. Clinical Procedures and Therapies

## A. Perform nuclear medicine procedures

- 1. Pulmonary
  - a. Radioaerosol ventilation
  - b. Gas ventilation
  - c. Perfusion
    - i. SPECT
    - ii. SPECT/CT
  - d. Perfusion/Ventilation quantitation
- 2. Bone/Musculoskeletal scans
  - a. Limited
  - b. Whole-body
  - c. 3-phase
  - d. 4-phase
  - e. SPECT
  - f. SPECT/CT
  - g. NaF PET
- 3. Oncology
  - a. Ga-67 tumor imaging, planar and/or SPECT
  - b. SPECT/CT
  - c. Peptide imaging
  - d. Molecular breast imaging
  - e. Lymphoscintigraphy/sentinel lymph node localization
  - f. Tumor imaging, PET
    - i. Melanoma (e.g., whole body)
    - ii. PSMA

**40**%

- iii. Neuroendocrine
- iv. Neurology
- v. General (e.g., skull-base to mid-thigh)
- g. Neuroendocrine tumor imaging
- 4. Infection
  - a. Ga-67 infection imaging
  - b. Tagged WBC imaging
- 5. Renal/Genitourinary
  - a. Cystogram, direct
  - b. Effective renal plasma flow (ERPF)
  - c. Glomerular filtration rate (GFR) imaging
  - d. Glomerular filtration rate (GFR) non-imaging
  - e. Renal anatomy, planar, SPECT (e.g., DMSA)
  - f. Renal flow
  - g. Renogram (Lasix®)
  - h. Renogram with ACE inhibitors
- 6. Endocrine
  - a. Adrenal imaging
  - b. Parathyroid imaging, planar and SPECT
  - c. SPECT/CT
  - d. Thyroid imaging
  - e. Thyroid uptake
  - f. Whole body survey for thyroid metastases
- 7. Hematopoietic
  - a. Bone marrow imaging
- 8. Cardiovascular
  - a. Myocardial perfusion, planar
  - b. Myocardial perfusion (gated and non-gated)
    - i. SPECT (e.g., supine, prone)
    - ii. SPECT/CT
    - iii. CT attenuation
    - iv. PET
  - c. Cardiac sarcoidosis
    - i. PET
  - d. First pass for EF and wall motion
  - e. Gated cardiac blood pool, rest
  - f. Gated cardiac blood pool, stress
  - g. Gated cardiac blood pool, SPECT
  - h. Cardiac shunt
  - i. Cardiac Amyloidosis
  - j. MIBG
  - k. Myocardial viability
    - i. Thallium
    - ii. FDG
- 9. Gastrointestinal

- a. Gastric emptying (liquid/solid)
- b. Gastroesophageal reflux
- c. Gastrointestinal bleeding
- d. Hemangioma
- e. Hepatobiliary with and without GBEF
- f. Liver-lung shunt mapping (arterial)
- g. Liver-spleen imaging, planar and SPECT
- h. SPECT/CT
- i. Meckel's diverticulum
- 10. Central Nervous System
  - a. Brain flow, brain death
  - b. Brain imaging, planar and SPECT
    - i. Brain perfusion SPECT (Acetazolamide)
    - ii. Viability SPECT
    - iii. Tumor SPECT
  - c. SPECT/CT
  - d. Dopamine transporter DaTscan®
  - e. Cisternogram
  - f. CSF leak
  - g. CSF shunt patency
  - h. Amyloid
  - i. Ictal and interictal (e.g., SPECT/planar, PET)
- 11. Radionuclide Therapy
  - a. I-131 sodium iodide for ablation
  - b. I-131 sodium iodide for hyperthyroid
  - c. Lu-177 Dotatate (Lutathera®)
  - d. Lu-177 PSMA (Pluvicto®)
  - e. Ra-223 Dichloride (Xofigo®)
  - f. Sr-89 Chloride (Metastron®)
  - g. Y-90 labeled microspheres
- 12. CT Imaging Procedures
  - a. Attenuation correction
  - b. Anatomical localization
  - c. Diagnostic vs non-diagnostic

#### **B. Schedule patient studies**

- 1. Camera duration
- 2. Multiple radionuclide procedures for a single patient
- 3. Same-day multiple modality procedures for a single patient

## C. Procure supply of radiopharmaceuticals

- 1. License parameters and limits (i.e., Institutional)
- 2. Reconciliation of schedule with radiopharmaceutical/adjunct pharmaceutical procurement

#### D. Educate patient, family, and personnel

- 1. Procedures
- 2. Precautions

- 3. Restrictions
- 4. Release criteria (e.g., inpatient, travel, therapy)
- 5. Consent (e.g., written and verbal)

## E. Obtain patient information and provide patient care

- 1. Patient information and privacy (e.g., Healthcare Insurance Portability and Accountability Act (HIPAA))
- 2. Basic patient care (e.g., vital signs, basic first aid, infection control)
- 3. Patient transferring techniques
- 4. Patient support devices (e.g., Foley catheter and drainage bag)
- 5. Patient identification (e.g., armband, verbal, scan)
- 6. Orders for study
- 7. Pre-examination screening
  - a. Patient preparations and contraindications
  - b. Medical history
  - c. Current medications
  - d. Allergic and adverse reaction history
  - e. Review relevant lab values
- 8. Informed consent
- 9. Disposal of supplies and biohazardous material
- 10. Emergency procedures (e.g., fainting, seizure, cardiopulmonary arrest)
- 11. Post-procedure assessment

## F. Select and administer prescribed radiopharmaceuticals

- 1. Patient/ radiopharmaceutical reconciliation
- 2. Calculation of appropriate volume to deliver prescribed dosage when needed
- 3. Radiopharmaceutical administration using appropriate route and technique

## G. Prepare equipment and perform examinations

- 1. Patient positioning (e.g., anatomical markers, immobilization techniques)
- 2. Imaging parameters for data acquisition

#### H. Evaluate image quality

- 1. Normal and abnormal scan patterns
- 2. Artifacts and causes
- 3. Co-registration of images (SPECT/CT and PET/CT)
- 4. Study repetition and additional views

#### I. Perform image processing

- 1. Data storage, transfer, and retrieval
- 2. Image formation (e.g., static, dynamic, gating, list mode)
- 3. Image reconstruction (e.g., SPECT, PET/CT)
- 4. Image enhancement (e.g., filters, matrix, intensity)
- 5. Quantitative analysis
  - a. Regions of interest and quantification
  - b. Curve generation and analysis
  - c. Image normalization and subtraction
- 6. Display formatting (image size, number of images, intensity adjustments)

#### J. Prepare/perform stress testing

1. Basic electrocardiography (ECG) (e.g., cardiac monitoring)

- a. Cardiac conduction system
- b. Components of a normal ECG wave form
- c. Recognizing and responding to changes on a resting or stress ECG
- 2. ECG lead placements
- 3. Treadmill stress techniques (e.g., Bruce and modified Bruce) and bicycle stress techniques
  - a. Contraindications
  - b. Duration/termination parameters
- 4. Pharmacological stress protocols
  - a. Contraindications
  - b. Timing of pharmacological stress agent
  - c. Timing of radiopharmaceutical injection
  - d. Duration/termination parameters
  - e. Drug side-effects and appropriate treatment
  - f. Reversal agents and techniques

## K. Obtain samples and/or data for non-imaging studies

- Data specimen collection techniques, including timing, methods, containers, and storage
- 2. Background correction
- 3. External counting techniques

## L. Evaluate the results of non-imaging studies

- 1. Error analysis
- 2. Calculations

## M. Administer radiopharmaceutical therapies

- 1. Isolation room requirements
- 2. Surveys
- 3. Inpatient vs outpatient
- 4. Storage and waste disposal
- 5. Documentation and record keeping
- 6. Post-therapy scanning
- 7. Dosimetry